Proactiveinvestors recommends
Additional Information
Market:ASX
Sector:Pharma & Biotech
EPIC:SPL
Latest Price: 1.60  (2.24% Ascending)
52-week High:1.86
52-week Low:0.96
Market Cap:447.88M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Starpharma Holdings

Starpharma Holdings (ASX: SPL) is focused on the development of dendrimer nanotechnology for pharmaceutical, drug delivery and other applications. Products based on Starpharma’s dendrimer technology are already on the market as diagnostic elements and laboratory reagents through licence agreements.

Pdf

Orbis acquires 2.5m Starpharma Holdings shares

Friday, August 27, 2010
Orbis acquires 2.5m Starpharma Holdings shares

Orbis Investment Management has boosted its shareholding in Melbourne-based biotech company Starpharma Holdings (ASX: SPL) on the 25 August 2010, acquiring 2.5 million shares at prices ranging from $0.49 per share.

Orbis now holds 12.5% of Starpharma.

Starpharma is a market leader in the development of nanotechnology products for pharmaceutical, life-science and other applications.

Starpharma’s lead product is VivaGel®, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes.

VivaGel® is at the expanded safety/Phase IIa stage of clinical development. VivaGel® has been granted Fast Track status by the US Food and Drug Administration (FDA), which will accelerate the clinical and regulatory process.

VivaGel® has been awarded US$20.3 million by the National Institutes of Health (NIH) to progress the development for HIV. The NIH has provided additional funding to develop VivaGel® against genital herpes.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.